Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
Clinical role
Concurrent reading aid for screening mammography and DBT interpretation.
Images and patients
Mammography/DBT · Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis
Key limitation
Keep in mind: The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.
Exact FDA record: K241831 · Agent source review · . This is not clinician review or local acceptance.
Within this record's scope
Consider for concurrent reading of screening FFDM and DBT from systems compatible with Transpara 2.1.0.
Limits to check
Region and examination scores support physician review. They must not be the sole basis for management, and do not establish a separate density-module license.
Questions for the vendor and your team
Which version, acquisition-system combinations and licensed outputs are included in the offer?
How will the team test displayed regions and exam scores alongside full image interpretation and record exceptions?
These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast; regions suspicious for cancer on screening mammography and digital breast tomosynthesis Input: DICOM full-field digital mammography and digital breast tomosynthesis examinations from compatible systems.
Who uses it?Intended users: Physicians qualified to interpret screening mammography and digital breast tomosynthesis.
What does the software produce?Output: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.
What is its most important limitation?Key limitation: The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.
Clinical takeaway. Clinical role: Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
Evidence takeaway. Evidence from the reviewed source record: K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.
Evidence context: questions, not a score
Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.
The main test set had 10,207 exams including 1,350 biopsy-proven cancers, from multiple centers in seven European countries and the US. Prior-exam analyses and manufacturer combinations are separate subgroups.
The summary reports non-inferior and superior standalone performance versus Transpara 1.7.2 and improved performance with temporal comparison versus without. Sensitivity depends on operating point and modality; false-positive rates are regions per image in non-cancer exams.
Standalone operating-point sensitivity is not an aided-reader outcome or a recall-rate guarantee. Subgroup and overlapping lesion classifications cannot be added. The existing separate literature study is not newly admitted or broadened by this card.
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
FFDM: Hologic, GE, Philips, Siemens and Fujifilm; DBT: Hologic, Siemens, GE and Fujifilm. Temporal-comparison combinations have a separate, narrower compatibility table.
Cancer: 1,350/10,207 exams; benign: 270/10,207; normal: 8,587/10,207. Lesion-type and histology categories are not summed across overlapping classifications.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Not established: No numerical age bound or explicit all-ages statement in the reviewed labeling sections. Study ages do not establish authorized age limits.
Transpara 2.1.0 is a concurrent reading aid for physicians interpreting screening full-field digital mammography and digital breast tomosynthesis, providing region and examination scores to support review of suspicious breast findings.
The FDA labeling states that the output is not the sole basis for patient management. Use is limited to compatible screening FFDM and DBT and requires physician review; the software does not replace interpretation.
K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K241831 FDA decision material reports the exact evidence metrics included below for Transpara 2.1.0; values are limited to the stated endpoint, population, and operating point.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
EndpointSensitivity at the FDA-reported operating point
Population5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
EndpointSensitivity at the FDA-reported operating point
Population4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
Population5,730 FFDM exams, including 750 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
Population4,477 DBT exams, including 600 with biopsy-proven cancer, from a multicenter test set representative of screening and diagnostic breast imaging practice
K241831 FDA evidence package for Transpara (2.1.0)
DesignFDA 510(k) standalone performance evaluation of FFDM and DBT exams from a multicenter test set representative of screening and diagnostic breast imaging practice.
Population10,207 examinations including 1,350 biopsy-proven cancers; FFDM and DBT cohorts from seven European countries and the United States.
Scopeexact submission
Tested versionTranspara 2.1.0
Samplen=10207
IndependenceSponsor or vendor study
K241831
FDA-reported results for the exact Transpara 2.1.0 submission.
Performance across different versions of an artificial intelligence model for screen-reading of mammograms
DesignRetrospective multicenter registry cohort comparing Transpara versions 1.7 and 2.1.
Population117,709 screening examinations including 737 screen-detected and 200 interval cancers from two breast centers.
Scopeexact product version
Tested versionTranspara 2.1
Samplen=117709
Sites2
IndependenceIndependence not established
PMID:41528472
The PubMed record explicitly identifies Transpara version 2.1. The article reports the major-minor release label; no broader Transpara-family claim is promoted.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K241831 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
Sectra IDS7
Not reviewed for this pairing
AI version: not established; system version: not established
Scope: product family; geography: Geography not established for this exact pairing
Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed.
Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build.
Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling.
Source review: 2026-11-06
Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
Installed-system acceptance has not been performed.
Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.
Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.
Reference baseline only. Installed build and AI compatibility remain to be established.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
Existing route context (at most two)
Broader supplier context
Not reviewed for this pairing
AI version: not established; system version: not established
Scope: product family; geography: Geography not established for this exact pairing
Configuration: Sectra lists Transpara results in IDS7, MG CAD SR/SC, overlays and worklist integration. The compatible PACS version must be confirmed.
Condition: The marketplace listing does not bind Transpara 2.1.0 in K241831 to a named IDS7 build.
Local test needed: Confirm the AI release, IDS7/Core build, licensed integration and region, then test marks, scores, workflow and failure handling.
Source review: 2026-11-06
Broader product-family or vendor context. The exact AI release and system build pairing is not reviewed.
Installed-system acceptance has not been performed.
Public version baseline: 28.2; Announced version; availability unconfirmed; reviewed 2026-11-06.
Sectra's public program names IDS7 28.2 for a December 8, 2026 webinar. This establishes an announced version, not general availability or a site build. The public March 2026 conformance statement covers 28.1.
Reference baseline only. Installed build and AI compatibility remain to be established.
Source context, not route validation: The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM mammography CAD results with marked calcification groups, soft-tissue regions, region scores, and an examination score.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.
The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.
ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Use by physicians qualified to interpret screening mammography and digital breast tomosynthesis. Follow the exact labeling, local training, supervision, and escalation requirements.
The FDA package describes a standalone processing appliance with a third-party workstation interface; current hosting, contracts, availability, security, and site configuration remain unknown.
The FDA package describes DICOM mammography input and CAD output to a workstation, PACS, or RIS through a standalone processing appliance and third-party workstation interface.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.
Transpara 1.7.2 · K221347. Name for this exact FDA record, not an alias for every commercial configuration. Name source
Transpara 2.1.0 · K241831. Name for this exact FDA record, not an alias for every commercial configuration. Name source
Transpara reading aid
Concurrent screening mammography and DBT reading aid. Applies to K221347, K241831. This describes the mapped function only; feature parity and a shared license are not established.
K241831 · 2024-11-25. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
18Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
Promoted PMID 41528472 because its record explicitly tests Transpara version 2.1. The other 17 PubMed records and all 6 trial records were quarantined because they are unrelated, unversioned, or test Transpara 1.6, 1.7, 1.7.1, 1.7.3, or 2.0.0 rather than the exact 2.1 release. The current discovery snapshot contains 18 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.